Sanofi receives positive CHMP opinion for Sarclisa for the treatment of relapsed and refractory multiple myeloma.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Sarclisa (isatuximab). The CHMP recommends Sarclisa in combination with pomalidomide… read more.